Hostname: page-component-78c5997874-fbnjt Total loading time: 0 Render date: 2024-11-06T00:23:42.060Z Has data issue: false hasContentIssue false
  • English
  • Français

Proliferating Cell Nuclear Antigen Expression in the Survival of Astrocytoma Patients

Published online by Cambridge University Press:  18 September 2015

L.C. Ang ,
M. Plewes ,
L. Tan ,
H. Begley ,
A. Agranovich  and
D. Shul
L.C. Ang
Affiliation:
Department of Pathology, Sunnybrook Health Science Centre, University of Toronto, Toronto
M. Plewes
Affiliation:
Department of Pathology, Royal University Hospital and University of Saskatchewan, Saskatoon
L. Tan
Affiliation:
Department of Community Health and Epidemiology, and University of Saskatchewan, Saskatoon
H. Begley
Affiliation:
Department of Pathology, Sunnybrook Health Science Centre, University of Toronto, Toronto
A. Agranovich
Affiliation:
Department of Radiational Oncology, University of Saskatchewan and Saskatoon Cancer Clinic, Saskatoon
D. Shul
Affiliation:
Department of Pathology, Royal University Hospital and University of Saskatchewan, Saskatoon
Rights & Permissions [Opens in a new window]

Abstract:

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

The PC 10, a monoclonal antibody against proliferating cell nuclear antigen (PCNA), is known to show immunoreactivity in routinely processed paraffin embedded tissue. This antibody was applied to 72 astrocytic tumours from surgical biopsy material obtained in a ten year period. The PCNA labelling index (LI) obtained by image analysis was compared with patient’s survival, age at diagnosis, and Karnofsky score as well as the histological grade of tumour. The survival analysis shows that patients with tumour PCNA LI of more than 6% have significantly poorer prognosis than those with 6% and below. In addition, there is also good correlation between PCNA LI with age, Karnofsky and tumour grade. This study suggests that although the PCNA expression of astrocytoma could be a useful predictor of patient’s outcome, it is not an independent prognostic factor but has derived its statistical association with survival secondarily through its relationship with tumour grade, age and Karnofsky score.

Résumé:

Résumé:

Expression de l’antigène nucléaire des cellules en prolifération comme prédicteur de la survie chez les patients atteints d’astrocytome. Le PC10, un anticorps monoclonal dirigé contre l’antigène nucléaire des cellules en prolifération (PCNA) démontre une immunoréactivité dans les tissus inclus dans la paraffine par la technique de routine. Cet anticorps a été appliqué à 72 tumeurs astrocytaires provenant de biopsies chirurgicales obtenues sur une période de dix ans. L’indice de marquage par le PCNA obtenu pas analyse d’image a été analysé en fonction de la survie des patients, à l’âge au moment du diagnostic, au score de Karnofsky et au stade de la tumeur. L’analyse de survie montre que les patients ayant un indice de plus de 6% ont un pronostic significativement plus sombre que ceux dont l’indice est de 6% ou moins. De plus, il existe également une bonne corrélation entre l’indice de marquage par le PCNA et l’âge, le score de Karnofsky et le stade de la tumeur. Cette étude suggère que, bien que l’expression du PCNA de l’astrocytome puisse être un porédicteur utile du devenir du patient, ce n’est pas un facteur pronostique indépendant parce que son association statistique avec la survie est secondaire à sa relation avec le stade de la tumeur, l’âge et le score de Karnofsky.

Type
Original Articles
Information
Canadian Journal of Neurological Sciences , Volume 21 , Issue 4 , November 1994 , pp. 306 - 310
Copyright
Copyright © Canadian Neurological Sciences Federation 1994

References

REFERENCES

1. Kernohan, JW, Sayre, GP. Tumors of the central nervous system. In: Atlas of Tumor Pathology, Section 10, Vols 35 and 37. Washington: Armed Forces Institute of Pathology; 1952.Google Scholar
2. Kleihues, P, Berger, PC, Scheithauer, BW. Histologic typing of tumours of the central nervous system. In: International Histologic Classification of Tumours. Geneva: World Health Organization; 1993; 11–14.Google Scholar
3. Burger, PC, Vogel, FS, Green, SB, Strike, TA. Glioblastoma multiforme and anaplastic astrocytoma. Cancer 1985; 56: 1106–1111.Google Scholar
4. Nelson, JS, Tsukada, Y, Schoenfeld, D, et al. Necrosis as a prognostic criterion in malignant supratentorial, astrocytic gliomas. Cancer 1983; 52: 550–554.Google Scholar
5. Daumas-Duport, C, Scheithauer, B, O’Fallon, J, Kelly, P. Grading of astrocytomas, a simple and reproducible method. Cancer 1988; 62:2152–2165.Google Scholar
6. Hall, PA, Levison, DA, Woods, AL, et al. Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: an index of cell proliferation with evidence of deregulated expression in some neoplasms. J Pathol 1990: 162: 285–294.Google Scholar
7. Bravo, R, MacDonald-Bravo, H. Existence of two populations of cyclin/proliferating cell nuclear antigen during the cell cycle: association with DNA replication sites. J Cell Biol 1987; 105: 1549–1554.Google Scholar
8. Bravo, R, Frank, R, Bludell, PA, Macdonald-Bravo, H. Cyclin/PCNA is the auxiliary protein of DNA polymerase-δ. Nature 326: 515.Google Scholar
9. Celis, JE, Celis, A. Cell cycle-dependent variations in the distribution of the nuclear protein cyclin, a proliferating cell nuclear antigen in cultured cells: subdivision of S phase. Proc Natl Acad Sci USA, 1985; 82:3262–3266.CrossRefGoogle Scholar
10. Kurki, P, Vanderlaan, M, Dolbeare, F, Gray, J, Tan, EM. Expression of proliferating cell nuclear antigen (PCNA)/cyclin during the cell cycle. Exp Cell Res 1986; 166: 209–219.Google Scholar
11. Jain, S, Filipe, MI, et al. Prognostic value of proliferating cell nuclear antigen in gastric carcinoma. J Clin Pathol 1991; 44: 655–659.Google Scholar
12. Woods, AL, Hall, PA, Shepherd, NA, et al. The assessment of proliferating cell nuclear antigen (PCNA) immunostaining in primary gastrointestinal lymphomas and its relationship to histological grade, S + G2 + M phase fraction (flow cytometric analysis) and prognosis. Histopathology 1991; 19: 21–27.Google Scholar
13. Yu, CC-W, Fletcher, CDM, Camplejohn, RS, et al. Haemangio-pericytomas: the prognostic value of immunohistochemical staining with a monoclonal antibody to proliferating cell nuclear antigen (PCNA). Histopathology 1991; 19: 29–33.Google Scholar
14. Louis, DN, Edgerton, S, Thor, AD, Hedley-Whyte, ET. Proliferating cell nuclear antigen and Ki-67 immunohistochemistry in brain tumors: a comparative study. Acta Neuropathol 1991; 81: 675–679.Google Scholar
15. Allegranza, A, Girlando, S, Arrigoni, GL, et al. Proliferating cell nuclear antigen expression in central nervous system neoplasms. Virchows Archiv A Pathol Anat 1991; 419: 417–423.Google Scholar
16. Karamitopoulou, E, Perentes, E, Melachrinou, M, Maraziotis, T. Proliferating cell nuclear antigen immunoreactivity in human central nervous system neoplasms. Acta Neuropathol 1993; 85: 316–322.Google Scholar
17. Theunissen, PHMH, Blaauw, G. Proliferating cell nuclear antigen immunostaining and survival in cerebral astrocytoma. Histopathology 1993; 23:75–79 Google Scholar
18. Byar, DP, Green, SB, Strike, TA. Prognostic factors for malignant Glioma. In: Walker, MD, ed. Oncology of the Nervous System. Boston/The Hague/Dordrecht/Lancaster, Martinus Nijhoff Publishers, 1983: 379–395.Google Scholar
19. Morris, GF, Mathews, MB. Regulation of proliferating cell nuclear antigen during the cell cycle. J Biol Chem 1991; 264: 13856–13864.Google Scholar
20. Bravo, R, Macdonald-Bravo, H. Induction of the nuclear protein ‘cyclin’ in quiescent mouse 3T3 cells stimulated by serum and growth factors. Correlation with DNA synthesis. EMBO J 1984: 3; 3177–3181.Google Scholar
21. Jaskulski, D, Gatti, C, Travali, S, Calabretta, B, Baserga, R. Regulation of the proliferating cell nuclear antigen cyclin and thymidine kinase mRNA levels by growth factors. J Biol Chem 1988; 263: 10175–10179.Google Scholar
22. Libermann, TA, Razon, N, Bartal, AD, et al. Expression of epidermal growth factor receptors in human brain tumors. Cancer Res 1984:753–760.Google Scholar
23. Gammeltoft, S, Ballotti, R, Kowalski, A, Westermark, B, Van Obberghen, E. Expression of two types of receptor for insulinlike growth factors in human malignant glioma. Cancer Res 1988; 48: 1233–1237.Google Scholar
24. Nister, M, Libermann, TA, Betsholtz, C, et al. Expression of messenger RNAs for platelet-derived growth factor and transforming growth factor-a and their receptor in human malignant glioma cell lines. Cancer Res 1988; 48: 3910–3918.Google Scholar
25. Reifenberger, G, Prior, R, Deckert, M, Wechsler, W. Epidermal growth factor receptor expression and growth fraction in human tumours of the nervous system. Virchows Archiv A Pathol Anat 1989; 414: 147–155.Google Scholar
26. Ito, M, Tsurusawa, M, Zha, Z, et al. Cell proliferation in childhood acute leukemia. Cancer 1992; 69: 2176–2182.Google Scholar
27. Theunissen, PHMH, Leers, MPG, Bollen, ECM. Proliferating cell nuclear antigen (PCNA) expression in formalin-fixed tissue of non-small cell lung carcinoma. Histopathology 1992; 20: 251–255.Google Scholar
28. Galand, P, Degraef, C. Cyclin/PCNA immunostaining as an alternative to tritiated thymidine pulse labelling for marking S phase cells in paraffin sections from animal and human tissues. Cell Tissue Kinet 1989; 22: 383–392.Google Scholar
29. Dervan, PA, Magee, HM, Buckley, C, Carney, DN. Proliferating cell nuclear antigen counts in formalin-fixed paraffin-embedded tissue correlate with Ki-67 in fresh tissue. Am J Clin Pathol 1992; 97: (Suppl 1): S21–S28.Google Scholar
30. Kawakita, N, Seki, S, Yanai, A, et al. Immunocytochemical identification of proliferative hepatocytes using monoclonal antibody to proliferating cell nuclear antigen (PCNA/cyclin). Am J Clin Pathol 1992; 97 (Suppl 1): S14–S20.Google Scholar
31. Smith, FG, Murray, PG, Crocker, J. Correlation between PCNA and AgNOR scores in non-Hodgkin’s lymphomas using sequential staining technique. J Clin Pathol 1993; 46: 28–31.Google Scholar
32. Linden, MD, Torres, FX, Kubus, J, Zarbo, RJ: Clinical application of morphologic and immunocytochemical assessments of cell proliferation. Am J Clin Pathol 1992; 97 (Suppl I): S4–S12.Google Scholar